QI
BMRN icon

QS Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History

QS Investors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$249K Hold
2,974
– – ﹤0.01% 1000
2021
Q1 		$225K Sell
2,974
-1,200
-29% -$98K ﹤0.01% 1076
2020
Q4 		$366K Buy
4,174
+479
+13% +$38K ﹤0.01% 919
2020
Q3 		$282K Hold
3,695
– – ﹤0.01% 944
2020
Q2 		$456K Sell
3,695
-600
-14% -$59.6K 0.01% 929
2020
Q1 		$363K Sell
4,295
-1,200
-22% -$103K 0.01% 919
2019
Q4 		$462K Hold
5,495
– – ﹤0.01% 961
2019
Q3 		$371K Hold
5,495
– – ﹤0.01% 1031
2019
Q2 		$471K Hold
5,495
– – 0.01% 989
2019
Q1 		$489K Sell
5,495
-12
-0.2% -$1.11K 0.01% 986
2018
Q4 		$469K Hold
5,507
– – 0.01% 925
2018
Q3 		$534K Sell
5,507
-1,769
-24% -$177K 0.01% 944
2018
Q2 		$685K Buy
7,276
+10
+0.1% +$876 0.01% 873
2018
Q1 		$589K Hold
7,266
– – 0.01% 901
2017
Q4 		$648K Buy
7,266
+185
+3% +$16.1K 0.01% 880
2017
Q3 		$659K Sell
7,081
-7
-0.1% -$619 0.01% 885
2017
Q2 		$644K Sell
7,088
-900
-11% -$81.9K 0.01% 864
2017
Q1 		$701K Buy
7,988
+6,200
+347% +$552K 0.01% 875
2016
Q4 		$148K Hold
1,788
– – ﹤0.01% 1183
2016
Q3 		$165K Buy
1,788
+5
+0.3% +$471 ﹤0.01% 1130
2016
Q2 		$139K Sell
1,783
-8
-0.4% -$680 ﹤0.01% 1179
2016
Q1 		$148K Sell
1,791
-304
-15% -$24.7K ﹤0.01% 1138
2015
Q4 		$219K Buy
2,095
+16
+0.8% +$1.67K ﹤0.01% 1071
2015
Q3 		$219K Hold
2,079
– – ﹤0.01% 1050
2015
Q2 		$284K Hold
2,079
– – ﹤0.01% 997
2015
Q1 		$259K Hold
2,079
– – ﹤0.01% 1003
2014
Q4 		$188K Buy
+2,079
New +$173K ﹤0.01% 1025

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

QS Investors's BMRN Position: Q2 2021 in Review

QS Investors held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2021 at 2,974 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

QS Investors first reported a position in BMRN in Q4 2014 and has held it in 27 quarters since. The position peaked at $701K in Q1 2017. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

  • QS Investors held 2,974 shares of BioMarin Pharmaceuticals worth $249K as of Q2 2021.
  • QS Investors left its BioMarin Pharmaceuticals share count unchanged in Q2 2021.
  • BioMarin Pharmaceuticals made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #1000 holding.
  • QS Investors first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
  • QS Investors's BioMarin Pharmaceuticals position peaked at $701K in Q1 2017.
  • 529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.